• Search
  • Helpdesk
  • Sales contact
Get your demo
☰

Strengthen your clinical trials data
with a strong eCOA strategy

Our eCOA experts together with our scientific and medical team will help you define impactful endpoints, explore relevant regulatory insights, select the most appropriate questionnaires, and determine the ideal data collection method tailored to your project’s needs.

Need advice?
  • Visualize the therapeutic value of your moleculethrough relevant patient insights.
  • Accelerate your market access by providing high-quality data to regulators and payers.
  • Improve the patient experienceby measuring what matters most to them with well-selected COAs.
  • Convince investors of the value of your productby reinforcing your dataset with strong eCOA data.

Engage early for COA/PRO value assessment

  • Evaluate the significance of PRO/endpoint selection: Our scientific advisory team helps you achieve a detailed understanding of the value of high-quality data. It will show you how eCOA data can strengthen your regulatory dossiers, and the added value of incorporating eCOAs into your protocol.
  • Explore the impact of eCOA in early-phase research: Understand the benefits of integrating eCOA strategies early in your clinical trials to maximize data quality and participant engagement, and save time for your market access steps.
  • Design protocol sections that matter: Collaborate with our team to develop relevant eCOA sections for your protocol, ensuring alignment with your clinical development plans and regulatory strategy.
  • Educate your team: Learn about the advantages of electronic data collection and how it can enhance your study's efficiency and accuracy.

Strengthen your eCOA strategy

Our scientific and medical team provides you with customized eCOA strategy recommendations that will propel your project forward:

  • Scientific assessment: Rigorously evaluate both disease-specific and generic COAs to ensure they meet your study's needs.
  • Regulatory insights: Thoroughly assess regulatory standards and review label approvals of PROs in your disease field with our experts.
  • Optimal frequency: Determine the best COA administration schedule to meet your clinical endpoints while considering the burden on participants and sites.
  • Deployment strategy: Implement a streamlined and effective eCOA operational plan in collaboration with our Product and Operations teams.
Contact OUR MEDICAL TEAM

Learn more about scientific and clinical support

See all resources

The importance of ePRO to support NASH/NAFLD unmet clinical research and medical needs

MetabolicScientific advice

NonAlcoholic SteatoHepatitis (NASH), now called Metabolic Dysfunction-Associated SteatoHepatitis (MASH), affects almost 115 million adults globally and is the most

The strengths of electronic Clinical Outcome Assessment (eCOA) versus paper solutions

eCOAScientific advice

In contrast to paper solutions, electronic Clinical Outcome Assessment (eCOA) demonstrates strengths such as: Accuracy Completeness Timings Attributability User-friendliness

The relevance of ePROs in early phase clinical trials

Scientific advice

Early phase clinical research (phase 1 and 2a) focuses on characterizing the behavior of the investigational product in humans,

Kayentis Europe
19 bis, chemin du vieux Chêne
38240 Meylan
France
Phone: +33 (0)4 76 00 54 20

Kayentis US
186 South Street
Suite 600
Boston, Massachusetts 02111
USA